mots c vs tirzepatide MOTS-C Legal Status 2026: FDA, DEA & State-by-State Rules A Synergistic Triad for Metabolic

India's pharmaceutical ecosystem has the potential to offer affordable GLP-1 alternatives to over 1 billion people globally , transforming this from purely a business opportunity into a critical public health imperative

We dont know what safety signals the phase 3 trials will reveal, and whenever you are looking at a new drug, the correct thing to do is be wary of the possibility of off target biologic effects that increase the risk of death

Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial

Individualized Medications: Created for specific patients

Wegovy: vergelijkbaar met Ozempic, maar hogere dosering mogelijk n goedgekeurd voor gewichtsverlies